A preclinical systematic review and meta-analysis assessing the impact of pharmacological PPARα activation in experimental renal injury is ongoing [132], and may help to inform the design of future preclinical and clinical studies of fibrate therapy in DKD. The gene discussed is PPARA; the disease is diabetic kidney disease.